MBX Biosciences, Inc. Common Stock (MBX) - Cash Flow Conversion Efficiency
Based on the latest financial reports, MBX Biosciences, Inc. Common Stock (MBX) has a cash flow conversion efficiency ratio of -0.046x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-20.21 Million) by net assets ($437.76 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See how leveraged is MBX Biosciences, Inc. Common Stock's balance sheet to measure how much of total assets are equity-financed.
MBX Biosciences, Inc. Common Stock - Cash Flow Conversion Efficiency Trend (2022–2025)
This chart illustrates how MBX Biosciences, Inc. Common Stock's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore how well can MBX Biosciences, Inc. Common Stock service its debt to assess how comfortably operating cash covers total debt obligations.
MBX Biosciences, Inc. Common Stock Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of MBX Biosciences, Inc. Common Stock ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Guangdong Mingyang Electric Co. Ltd. A
SHE:301291
|
N/A |
|
Melia Hotels
MC:MEL
|
0.178x |
|
Semapa
LS:SEM
|
0.059x |
|
KPIT Technologies Limited
NSE:KPITTECH
|
0.112x |
|
Shenzhen Fine Made Electronics Group Co Ltd
SHE:300671
|
-0.022x |
|
Australian United Investment Company Ltd
AU:AUI
|
0.021x |
|
Uwc Bhd
KLSE:5292
|
-0.012x |
|
China Tianying Inc
SHE:000035
|
0.013x |
Annual Cash Flow Conversion Efficiency for MBX Biosciences, Inc. Common Stock (2022–2025)
The table below shows the annual cash flow conversion efficiency of MBX Biosciences, Inc. Common Stock from 2022 to 2025. For the full company profile with market capitalisation and key ratios, see market value of MBX Biosciences, Inc. Common Stock.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $369.22 Million | $-79.95 Million | -0.217x | -1.95% |
| 2024-12-31 | $257.44 Million | $-54.68 Million | -0.212x | -148.13% |
| 2023-12-31 | $-72.47 Million | $-31.98 Million | 0.441x | -18.69% |
| 2022-12-31 | $-42.60 Million | $-23.12 Million | 0.543x | -- |
About MBX Biosciences, Inc. Common Stock
MBX Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of precision peptide therapies for the treatment of endocrine and metabolic disorders. Its lead product candidate is Canvuparatide (MBX 2109), a parathyroid hormone peptide prodrug, which is in Phase 3 clinical trial for the treatment of chronic hypoparathyroidism. The company is also devel… Read more